Outcomes in surgical stage I uterine papillary serous carcinoma

Havrilesky, Laura J.; Secord, Angeles Alvarez; Bae‐Jump, Victoria L.; Ayeni, Tina A.; Calingaert, Brian; Clarke‐Pearson, Daniel L.; Berchuck, Andrew; Gehrig, Paola A.

doi:10.1016/j.ygyno.2007.01.041

Cited by 97 publications

(57 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[91][92][93][94][95] Adjuvant therapy recommendations for stage IA include observation and/or chemotherapy, or tumordirected RT. 96 Recommendations for stage 1B to II include chemotherapy with or without tumor-directed RT, or whole abdominopelvic RT with or without vaginal brachytherapy (category 3). Patients with adequately debulked stage III or IV disease can also undergo these procedures.…”

Section: Treatment Of Relapsed or Metastatic Diseasementioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Section: Treatment Of Relapsed or Metastatic Diseasementioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

“…Endometrial cancer is classified into two types, type I and type II, according to aggressiveness, prognosis and molecular characteristics (3). Type I endometrial cancer is thought to have slower growth, hormone sensitivity, low stage and an excellent prognosis (4). Approximately 10% of endometrial cancer cases are type II lesions which are high grade with deep invasion into the underlying myometrium and represent more aggressive malignancies (5).…”

Section: Introductionmentioning

confidence: 99%

Additional effects of engineered stem cells expressing a therapeutic gene and interferon-β in a xenograft mouse model of endometrial cancer

Kim

Choi

2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Endometrial cancer is the most common gynecologic malignancy in women worldwide. In the present study, we evaluated the effects of neural stem cell-directed enzyme/prodrug therapy (NDEPT) designed to more selectively target endometrial cancer. For this, we employed two different types of neural stem cells (NSCs), HB1.F3.CD and HB1.F3.CD.IFN-β cells. Cytosine deaminase (CD) can convert the non-toxic prodrug, 5-fluorocytosine (5-FC), into a toxic agent, 5-fluorouracil (5-FU), which inhibits DNA synthesis. IFN-β is a powerful cytotoxic cytokine that is released by activated immune cells or lymphocytes. In an animal model xenografted with endometrial Ishikawa cancer cells, the stem cells stained with CM-DiI were injected into nearby tumor masses and 5-FC was delivered by intraperitoneal injection. Co-expression of CD and IFN-β significantly inhibited the growth of cancer (~50-60%) in the presence of 5-FC. Among migration-induced factors, VEGF gene was highly expressed in endometrial cancer cells. Histological analysis showed that the aggressive nature of cancer was inhibited by 5-FC in the mice treated with the therapeutic stem cells. Furthermore, PCNA expression was more decreased in HB1.F3.CD.IFN-β treated mice rather than HB1.F3.CD treated mice. To confirm the in vitro combined effects of 5-FU and IFN-β, 5-FU was treated in Ishikawa cells. 5-FU increased the IFN-β/receptor 2 (IFNAR2) and BXA levels, indicating that 5-FU increased sensitivity of endometrial cancer cells to IFN-β, leading to apoptosis of cancer cells. Taken together, these results provide evidence for the efficacy of therapeutic stem cell-based immune therapy involving the targeted expression of CD and IFN-β genes at endometrial cancer sites.

show abstract

“…Although comprising only about 10B15% of endometrial cancers, endometrial serous carcinoma is known for its aggressive behavior and poor prognosis, accounting for more than 40% of endometrial cancer deaths. 4,5 One reason for the poor prognosis of endometrial serous carcinoma is its association with extrauterine disease or pelvic serous carcinoma. Pelvic serous carcinoma is mainly derived from adnexa and endometrial serous carcinoma.…”

mentioning

confidence: 99%

Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma

Zeng

Wang

et al. 2015

Modern Pathology

View full text Add to dashboard Cite

Serous endometrial intraepithelial carcinoma is often associated with extrauterine disease. It is currently unclear where does the extrauterine disease come from. This study addressed this issue. A total of 135 samples from 21 serous endometrial intraepithelial carcinoma patients were studied. Cellular lineage relationships between intrauterine and extrauterine serous carcinomas were determined by TP53-mutation analysis and correlated to the clinicopathologic features. There were three conditions contributing the extrauterine disease: metastasis from serous endometrial intraepithelial carcinoma (n ¼ 10) showed identical TP53 mutation between intrauterine lesions and extrauterine disease, cases of adnexal origin (n ¼ 5) had discordant TP53 mutations, and the mixed cellular origin cases (n ¼ 6) with both identical and discordant mutation status. Patients with extrauterine disease from serous endometrial intraepithelial carcinoma metastasis typically had small tumor masses (o2 cm) in extrauterine sites and without finding of serous tubal intraepithelial carcinoma, while extrauterine disease with adnexal or tubal origin commonly had larger tumor masses in extrauterine sites including ovary and omentum and serous tubal intraepithelial carcinoma. The majority of extrauterine diseases associated with serous endometrial intraepithelial carcinoma are metastasized from the endometrium. Serous endometrial intraepithelial carcinoma is frequently associated with serous cancers of adnexal or tubal origin, indicating that endometrial and adnexal or tubal serous cancers may share similar etiologies. TP53-mutation analysis provides a strong linkage for cellular lineage analysis. Tumor size in extrauterine disease and presence of serous tubal intraepithelial carcinoma or not are useful clinicopathologic features to determine primary cancer site, which helps in clinical management.

show abstract

Outcomes in surgical stage I uterine papillary serous carcinoma

Cited by 97 publications

References 20 publications

Uterine Neoplasms

Uterine Neoplasms

Additional effects of engineered stem cells expressing a therapeutic gene and interferon-β in a xenograft mouse model of endometrial cancer

Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma

Contact Info

Product

Resources

About